Work

Supplementary Figure 1 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 1. Suppression of MAPK pathway activation at the RP2D in colorectal cancer and pancreatic cancer patients. GDC-0994 modulates MAPK pathway-regulated gene transcription at the RP2D. Note: there were no partial responses in this group of patients.

DOI: 10.1158/1078-0432.22479705

Authors: Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, Patricia LoRusso, Johanna Bendell, Shih-Min A. Huang, Marie-Claire Wagle, Kwame Okrah, Lichuan Liu, Elaine Murray, Sandra M. Sanabria-Bohorquez, Michael Tagen, Hatem Dokainish, Lars Mueller, Howard Burris

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362412937

Cites:

Cited by:

Related to: 10